Filter by Lead Doctor (All Doctors) Parvin Peddi, M.D.Janie Grumley, M.D.Erwin Grussie, M.D. Title Physician Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab NCT ID : 05812807 Protocol Number : A012103 Phase : 3 Location : Saint John's Cancer Institute Parvin Peddi, M.D. Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions NCT ID : 05068726 Protocol Number : GE-280-401 Phase : 4 Location : Saint John's Cancer Institute Parvin Peddi, M.D. Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT. NCT ID : 03488693 Protocol Number : CCTGMA.39 Phase : 3 Location : Santa Monica, CA Janie Grumley, M.D. Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer NCT ID : 04958785 Protocol Number : GS-US-586-6144 Phase : 2 Location : Saint John's Cancer Institute Parvin Peddi, M.D. Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study NCT ID : 05568472 Protocol Number : SWOG-S2010 Phase : 3 Location : Saint John's Cancer Institute Janie Grumley, M.D. A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania) NCT ID : 04873362 Protocol Number : WO42633 Phase : 3 Location : Disney Family Cancer Center Erwin Grussie, M.D.